How should a patient with a 2 g/dL IgG paraprotein and immune paresis be evaluated and managed?

Evaluation and Management of 2 g/dL IgG Paraprotein with Immune Paresis

A patient with a 2 g/dL (20 g/L) IgG paraprotein and immune paresis requires bone marrow examination and imaging to exclude multiple myeloma or smoldering myeloma, followed by risk stratification and ongoing surveillance if MGUS is confirmed. 1, 2

Initial Diagnostic Workup

The presence of immune paresis (suppression of uninvolved immunoglobulins) alongside a 2 g/dL IgG paraprotein places this patient in a higher-risk category that mandates comprehensive evaluation:

Required Laboratory Tests

• Complete blood count with differential - assess for anemia
• Comprehensive metabolic panel - specifically calcium, creatinine, and albumin to detect myeloma-defining events
• Serum protein electrophoresis with immunofixation - confirm M-protein type
• Serum free light chain (FLC) assay - critical for risk stratification 2
• Quantitative immunoglobulins - document degree of immune paresis
• 24-hour urine protein electrophoresis with immunofixation - detect Bence Jones proteinuria
• Beta-2 microglobulin and LDH - prognostic markers if myeloma suspected

Bone Marrow Examination - MANDATORY

Bone marrow aspirate and biopsy must be performed because this patient has a 20 g/L IgG paraprotein (above the 15 g/L threshold) AND immune paresis. 1 The European Myeloma Network guidelines explicitly state that bone marrow examination should be part of the diagnostic workup for IgG M-proteins >15 g/L. The presence of immune paresis further elevates concern, as research demonstrates that immune paresis correlates with higher MGUS risk categories and increased likelihood of underlying plasma cell burden. 3

The bone marrow should include:

• Plasma cell percentage quantification
• Flow cytometry for aberrant plasma cell phenotype (≥95% aberrant cells significantly increases progression risk) 2
• Cytogenetics and FISH panel to exclude myeloma-associated abnormalities

Imaging Studies - REQUIRED

Perform skeletal imaging to exclude lytic bone lesions. Options include:

• Low-dose whole-body CT - preferred over conventional skeletal survey due to superior sensitivity 1
• Conventional skeletal survey remains acceptable if CT unavailable

The guideline threshold for omitting imaging is ≤15 g/L for IgG without bone pain; this patient exceeds that threshold. 1

Risk Stratification After Excluding Myeloma

If the workup confirms MGUS (M-protein <30 g/L, bone marrow plasma cells <10%, no end-organ damage), stratify progression risk using the Mayo Clinic model 2:

Three risk factors predict progression:

1. M-protein ≥15 g/L (this patient has 20 g/L - PRESENT)
2. Non-IgG type (this patient has IgG - ABSENT)
3. Abnormal FLC ratio (requires testing - UNKNOWN)

Risk of progression to myeloma at 20 years:

• 0 risk factors: 5%
• 1 risk factor: 21%
• 2 risk factors: 37%
• 3 risk factors: 58%

This patient has at least 1 risk factor (M-protein 20 g/L), placing them in at minimum the low-intermediate risk category. The FLC ratio result will determine if they have 2 risk factors (high-intermediate risk).

Clinical Significance of Immune Paresis

The presence of immune paresis is clinically important for several reasons:

• Increased infection risk - suppressed polyclonal immunoglobulins impair normal immune function 1
• Correlation with disease burden - immune paresis severity correlates with MGUS risk category and plasma cell burden 3
• Progression marker - worsening immune paresis during follow-up may signal evolution toward myeloma

However, immune paresis alone does NOT define treatment indication. Treatment is reserved for symptomatic myeloma or related disorders, not MGUS. 1, 2

Surveillance Protocol

Initial Follow-up

• Repeat serum protein electrophoresis in 6 months to confirm stability and exclude rapidly progressive disease (which would suggest initial misdiagnosis) 2

Long-term Monitoring Based on Risk

For intermediate or high-risk MGUS (≥1 risk factor):

• Serum protein electrophoresis and complete blood count annually for life 2
• Monitor for symptoms: bone pain, fatigue, recurrent infections, weight loss
• Repeat imaging or bone marrow only if clinical progression suspected

Low-risk MGUS (if FLC ratio normal):

• Follow-up every 2-3 years or when symptoms develop 2

When to Treat

Treatment is NOT indicated for MGUS, regardless of immune paresis severity, unless:

1. Progression to symptomatic multiple myeloma (CRAB criteria: hypercalcemia, renal failure, anemia, bone lesions)
2. Development of AL amyloidosis
3. MGUS-related organ damage (e.g., neuropathy, renal disease from monoclonal protein deposition)
4. Enrollment in a clinical trial 1, 2

Important Caveat on Immune Paresis and Infections

If the patient develops recurrent severe infections attributable to hypogammaglobulinemia, this represents a distinct clinical scenario. While not an indication to treat the plasma cell disorder itself, severe immune paresis with recurrent infections may warrant consideration of immunoglobulin replacement therapy, though this is controversial and not standard practice for MGUS. 4 This decision requires infectious disease or immunology consultation.

Common Pitfalls to Avoid

1. Assuming immune paresis alone indicates treatment - it does not; MGUS remains a watch-and-wait diagnosis
2. Omitting bone marrow examination - the 20 g/L M-protein level mandates this evaluation
3. Inadequate initial workup leading to missed myeloma diagnosis - ensure comprehensive evaluation before labeling as MGUS
4. Failure to assess FLC ratio - this is essential for accurate risk stratification
5. Prophylactic antibiotics or immunoglobulin replacement - not indicated for MGUS with immune paresis unless severe recurrent infections documented